{"podcast":{"title":"Blood Cancer Talks","slug":"blood-cancer-talks-5570002","podcast_index_feed_id":5570002,"rss_url":"https://feeds.transistor.fm/bloodcancertalks","website_url":null,"image_url":"https://img.transistorcdn.com/W_5G4oA5kAcf9vixuJQw-sMFE98Hvnnp4pex_BzuYvE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.jpg","author":"Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff","episode_count":75,"summary":"This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk","last_synced_at":"2026-09-03T22:19:58.611204+00:00","page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002"},"episode":{"title":"Episode 56. Management of Newly Diagnosed CML with Dr. Hagop Kantarjian","slug":"episode-56-management-of-newly-diagnosed-cml-with-dr-hagop-kantarjian","published_at":"2025-02-12T12:00:00+00:00","page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-56-management-of-newly-diagnosed-cml-with-dr-hagop-kantarjian","show_page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002","url":"https://share.transistor.fm/s/71e8c6ff","audio_url":"https://media.transistor.fm/71e8c6ff/c30a8834.mp3","summary":"In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed: 1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. https://pubmed.ncbi.nlm.nih.gov/38820078/ 2. 5-year follow-up of ENESTnd RCT (nilotinib): https://pubmed.ncbi.nlm.nih.gov/26837842/ 3. 10-year follow-up of ENESTnd RCT (nilotinib): https://pubmed.ncbi.nlm.nih.gov/33414482/ 4. 10-year follow-up of CML-IV RCT (imatinib): https://pubmed.ncbi.nlm.nih.gov/25676422/ 5. MD Anderson data on low-dose dasatinib (50 mg): https://pubmed.ncbi.nlm.nih.gov/36054032/ https://pubmed.ncbi.nlm.nih.gov/31553487/ 6. CML: 2025 update on diagnosis, therapy, and monitoring: https://pubmed.ncbi.nlm.nih.gov/39093014/","meta_description":"In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed: 1. ASC…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3775,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-56-management-of-newly-diagnosed-cml-with-dr-hagop-kantarjian/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-56-management-of-newly-diagnosed-cml-with-dr-hagop-kantarjian.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}